CONTENT HUB
Latest news
Here, you will find announcements, advancements in synthetic DNA technology, and insights into our contributions to the fields of vaccines, gene therapy, cell therapy and gene editing
4basebio and Neomatrix announce clinical material supply agreement to develop personalised cancer therapy utilising 4basebio’s proprietary hpDNA
25 MAY 2023
Press Release: 4basebio and Neomatrix announce clinical material supply agreement
Final Results, Notice of AGM and Related Party Transaction
11 MAY 2023
Press Release: Final results for financial year ended 31 December 2022
Signing of new lease and expansion of manufacturing capacity
3 APR 2023
Press Release: 4BB is relocating its manufacturing and quality assurance teams to new premises adjacent to its existing clean room facilities
Research collaboration for treatment of Neurofibromatosis Type 1
10 JUN 2022
Press Release: Announcement of collaboration with University of Alabama and Teesside University
Final Results and Notice of AGM
9 MAY 2022
Press Release: Results for the financial year ended 31 December 2021
Joint development agreement with Heqet Therapeutics for development of a non-viral vector therapy for cardiac regeneration
27 APR 2022
Press Release: Heqet to evaluate 4basebio’s Hermes® non-viral nanoparticle
Rapidly produced customisable synthetic DNA
23 MAR 2022
Press Release: Discover 4basebio’s new synthetic DNA offering
DNA manufacturing update
15 FEB 2022
Press Release: 4basebio welcomed senior hires across its manufacturing, quality assurance and business development teams
Strategic research collaboration evaluating linear DNA for mRNA production
18 JAN 2022
Press Release: Strategic research collaboration between 4basebio and eTheRNA